Stoke's Dravet Trial On Track, Yet Binary Risk Persists

What happened

Stoke Therapeutics' Q2 earnings call confirmed that the Phase III EMPEROR study of zorevunersen in Dravet syndrome completed enrollment ahead of the planned rolling new drug application submission, with data readout still expected in Q3 2027. The company reiterated that the 162-patient pivotal cohort was fully enrolled in 10 months and that the rolling NDA is set to begin in 1Q27, consistent with prior guidance. However, this progress was already reflected in the DeepValue master report, which highlighted the June 2026 enrollment completion and maintained a WAIT rating due to unresolved risks. Key uncertainties persist, including whether the FDA will align on the data package during the 2H26 pre-NDA meeting and whether competitor programs from Encoded and Ionis will compress Stoke's first-mover advantage. Additionally, the recent $65.7 million post-quarter ATM issuance extends the cash runway into early 2028, but it also dilutes existing shareholders ahead of the pivotal readout.

Implication

For investors, the investment thesis remains a WAIT as the on-track update is necessary but not sufficient to justify buying at current levels. The next critical catalyst is the pre-NDA meeting in the second half of 2026, where FDA alignment on the data package and statistical analysis plan must be explicitly confirmed. Until that clarity emerges, the risk-reward is balanced, with a bull case hinging on successful regulatory alignment and a bear case driven by potential FDA requests for additional studies or competitor progress. Given the single-asset binary risk and the stock's recent trading near $30, downside protection remains limited. Consequently, a more attractive entry point may arise on pullbacks toward $24 or after definitive regulatory clarity is achieved.

Thesis delta

The update aligns with the base case and does not alter the investment thesis. The fundamental uncertainties remain centered on FDA alignment, the sufficiency of the 162-patient package, and encroaching competition, none of which are addressed by this news. The rating stays WAIT with an attractive entry below $24.